Authors


Louise A. Winter RN, BSN

Latest:

Implementation and Usage of Data Monitoring Committees

Exploring sourcing model options for appropriate incorporation of DMCs into a clinical program.



Penelope K. Manasco, MD

Latest:

Oversight Method Identifies Critical Errors Missed by Traditional Monitoring Approaches

Study Health Check provides early identification of issues related to protocol deviations and determines objective measures of site-specific versus study-wide performance.


Julie Church-Thomas

Latest:

Clinical Trial Mobilization

Why should sponsors and CROs consider using mobile nursing for clinical trials?



Jennifer Goldsmith

Latest:

It’s Time to Transform Clinical Trial Operations

The need to move beyond a point-solutions approach to one built around applications designed to manage the end-to-end clinical trial process is crucial.


Michela Masoero

Latest:

European Pediatric Informed Consent and AF: Current Status of Country Requirements

The Pediatric Working Group of EUCROF launched an initiative to achieve standardization of generic Informed Consent Form and Assent Form templates within European countries. The differences are noted based on a prior survey.


Charles A. Knirsch

Latest:

Risk Assessment and Mitigation

A quantitative approach to enhancing risk assessment and mitigation in drug development.



Gordon Jones

Latest:

Proven Methodologies Resulting in Effective and Efficient CTA Process

The management and oversight of clinical trials agreement contracts are still handled through spreadsheets or document management systems ill equipped for an efficient CTA lifecycle.


Paula McHale

Latest:

Risk-Based Approaches

The eClinical Forum Risk Based Monitoring Taskforce offers some best practices for ensuring clinical data quality.



Catherine Ménard

Latest:

Partnering Early for Successful Oncology Drug Development

Rising costs and evolving compound developments underline need for understanding at every step.


Patrick Homer

Latest:

Advancing Human Healthcare Through Accessible Trial Data and Analytics

The Clinical Study Data Request consortium is actively pursuing platform interoperability to allow data to be merged and analyzed as an important step for advancing human healthcare.


Paulami Naik

Latest:

Clinical Supply Capabilities, Practices, and Perceptions Among Investigative Sites

Pressure to shorten study start-up timelines puts clinical supply management in the crosshairs.


Ben Comer

Latest:

Fine-Tuning CRO/Sponsor Interaction

Pharma needs to find a balance in working with Sponsors and CROs in order to streamline the study processes.


Gail Adinamis

Latest:

The Local Touch

Global reach for at-home study visits can accelerate clinical trials, says CEO.


Lisa Lucero

Latest:

Risk-Based Approaches

The eClinical Forum Risk Based Monitoring Taskforce offers some best practices for ensuring clinical data quality.



Kate McGowan

Latest:

Observations from AACR 2014

This year the AACR conference was focused on "Harnessing Breakthroughs, Targeting Cures."


Kathleen W. Wyrwich

Latest:

Personalized Healthcare

What works when and for whom in the era of comparative effectiveness research.


Charlie Morris

Latest:

Sustaining Innovation

Constant technological advancements continue to alter the compliance battle.


Selina Sibbald

Latest:

Risk-Based Approaches

The eClinical Forum Risk Based Monitoring Taskforce offers some best practices for ensuring clinical data quality.


Ashley Mehta

Latest:

Objective Internal Monitoring

Sponsors are responsible for monitoring studies, patient safety, and data integrity.



eyeforpharma

Latest:

State of the industry: Data & Technology in Clinical Trials

Teaming up with Eli Lilly and DrugDev Advisory Board, eyeforpharma conducted a 'State of the Industry' survey to investigate how pharma is currently leveraging data and technology and how this will change over the next 2 years. Highlights include: - Adopt a risk based approach for a cheaper way to clean your data, ensure optimum data quality and patient safety - Integrate real world and real time data for faster data generation, to quickly demonstrate value to patients and find urgent answers to unmet needs - Overcome rising R&D costs by utilizing big data to identify patient sub groups, integrate patients into research stages to better identify new biomarkers and provide more personalized treatments - See how mobile and wearable devices encourage patient participation by virtualizing parts of trials, reduce patient burden and enhance data quality


Paul O'Donohoe

Latest:

Treating Alzheimer's Early

The FDA has released its plan for pre-dementia Alzheimer's trials.


Michelle Foust

Latest:

Strengthening the Links in the Clinical Supply Chain: Aim for Transparency throughout the Process

Most business leaders acknowledge the pitfalls of organizational silos: they breed inefficiency and signal systemic malfunctioning.


Donelle Bussom RN, MSN

Latest:

Implementation and Usage of Data Monitoring Committees

Exploring sourcing model options for appropriate incorporation of DMCs into a clinical program.


Jesse M.Glass

Latest:

Are Phase III Clinical Trials Really Consistently Behind Schedule?

With a unique business model, pharmaceutical companies and their subcontractors need to find every way possible to shorten drug development times consistent with patient safety. The challenges facing commercially oriented organizations developing prescription drugs are substantial.

© 2024 MJH Life Sciences

All rights reserved.